Home » Unlabelled » FDA approves Imbruvica for rare blood cancer

FDA approves Imbruvica for rare blood cancer

You are subscribed to FDA Press Releases for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

11/13/2013 12:16 PM EST

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

Manage your FDA Subscriptions:

Update your preferences or unsubscribe
Questions about this service? support@govdelivery.com
Other inquiries? webmail@oc.fda.gov

This email was sent to aqeel.naseem87.Aqeel7879598@blogger.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420

Thank you for reading the article about FDA approves Imbruvica for rare blood cancer. If you want to duplicate this article you are expected to include links http://pharmacologyebooksdownload.blogspot.com/2013/11/fda-approves-imbruvica-for-rare-blood.html. Thank you for your attention.